Alkermes Presents New Clinical Data on ALKS 4230 in Mini Oral Presentation at 2020 European Society for Medical Oncology (ESMO) Virtual Congress

Author's Avatar
Sep 18, 2020
Article's Main Image

- Data Provide Evidence of Clinical Benefit and Tolerability of ALKS 4230 as Monotherapy in Melanoma and in Combination With Pembrolizumab in Multiple Tumor Types -

- Monotherapy Melanoma Cohort Expanded Based on Achievement of Protocol-Defined Response Criteria -

- Company to Host Investor Webcast at 8:30 a.m. ET on Friday, Sept. 18, 2020 -

PR Newswire